scispace - formally typeset
B

Bruce W. Bode

Researcher at Piedmont Hospital

Publications -  210
Citations -  17434

Bruce W. Bode is an academic researcher from Piedmont Hospital. The author has contributed to research in topics: Diabetes mellitus & Type 1 diabetes. The author has an hindex of 58, co-authored 183 publications receiving 14566 citations. Previous affiliations of Bruce W. Bode include Georgia Regents University.

Papers
More filters
Journal ArticleDOI

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, +798 more
- 27 Oct 2018 - 
TL;DR: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events, and evidence-based glucagon-like peptide 1 receptor agonists should be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events.
Journal ArticleDOI

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

TL;DR: Liraglutide is safe and effective as initial pharmacological therapy for type 2 diabetes mellitus and leads to greater reductions in HbA(1c), weight, hypoglycaemia, and blood pressure than does glimepiride.
Journal ArticleDOI

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial

TL;DR: This randomized, double-blind, placebo-controlled, parallel-group trial with 12-week observational off-drug follow-up period to investigate efficacy and safety of liraglutide vs placebo for weight management in adults with overweight or obesity and type 2 diabetes.
Journal ArticleDOI

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

TL;DR: In subjects with type 2 diabetes poorly controlled on OADs, initiating insulin therapy with twice-daily BIAsp 70/30 was more effective in achieving HbA(1c) targets than once-daily glargine, especially in subjects with Hb a( 1c) >8.5%.
Journal ArticleDOI

Threshold-based insulin-pump interruption for reduction of hypoglycemia

TL;DR: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values.